Clover Corporation Limited · ASX:CLV

Clover — Select Equities Healthcare & Wellbeing Investor Conference (May 2016)

16 slides from Clover's conference presentation, May 2, 2016

  1. Slide 1: Select Equities Healthcare & Wellbeing Investor Conference

    For personal use only Select Equities Healthcare & Wellbeing Investor Conference Clover Corporation Presentation Peter Davey – Managing Director & CEO 2 May 2016

  2. Slide 2: Vision and Mission Statement

    For personal use only Vision and Mission Statement Vision: To optimise the health and development of adults, infants and children. Mission: To deliver science based bioactives which provide health benefits to adults, infants, children and to the medical food markets.

  3. Slide 3: 2016 Half Year Performance

    2016 Half Year Performance For personal use only Highlights 9 Total Revenue up 9 Revenue from new 23.9% driven by customers is 16% improved demand continues positive trend $801K up 9 Net Profit 9 Inventory managed at 12.6% on half year $13m in line with 2015 revenue growth 9 Operating expenses down

  4. Slide 4: Clover's Value Chain

    For personal use only Clover’s Value Chain Omega 3 – EPA / DHA Omega 6 - ARA Product source Fish Single Cell Other Marine Crude processors Market Participants Refiners Clover primarily operates in this sector of the supply chain Encapsulation Sales and distribution Applications / Markets Dietary Foo

  5. Slide 5: Encapsulation Technology

    48% Oil For personal use only Encapsulation Technology 52% Encapsulant ƒ Patented Microencapsulation Technology with best in class application performance: D201.010 Driphorm HiDHA 50 ‒ Protection against oxidation and provides superior sensory stability ‒ Suitable for a wide range of food applicatio

  6. Slide 6: Company Overview

    For personal use only Company Overview ƒ Clover has three business units: Nu-Mega Ingredients, Medical (operated under a licensing agreement) as well as its research and development function Research & Medical R&D development Development of a phase 3 clinical trial product aimed at Clover Corporatio

  7. Slide 7: Market Update

    For personal use only Market Update Market changes Outcomes for Clover ƒ New Chinese infant formula regulations ƒ Regulated Chinese infant formula industry, ƒ New EU regulation requiring the mandatory increased quality controls positions Clover inclusion of DHA in infant formula by 2020 as a premium

  8. Slide 8: Half Year 2016 Results

    For personal use only Half Year 2016 Results

  9. Slide 9: Half Year 2016 Results

    For personal use only Half Year 2016 Results AUD million 4E Reported 4E Reported •23.9% year on year revenue 31 Jan 2016 31 Jan 2015 growth Revenue $19.7 $16.0 •Recovery of traditional markets Profit before $1.08 $0.91 and customers and encouraging tax growth in sales to new customers EBITDA $1.26 $

  10. Slide 10: Balance Sheet January 2016

    For personal use only Balance Sheet 31 January 2016 AUD million Reported Reported Movement 31 Jan 2016 31 July 2015 Cash $7.1 $9.6 2.5 È •Cash balance strong $7.1m Trade $11.1 $5.5 5.6 Ç Receivables •Trade receivables Inventories $13.1 $14.2 1.1 È reflect the increased Total Current $31.4 $29.5 1.9

  11. Slide 11: Pre-term

    For personal use only Pre-term

  12. Slide 12: Overview of Pre-term

    For personal use only Overview of Pre-term What is it? ƒ A phase 3 clinical trial product aimed at reducing broncho-pulmonary dysplasia (BPD) and cognitive impairment in pre-term infants through an enteral feeding device delivering high dose DHA The problem ƒ Pre-term infants are often subject to si

  13. Slide 13: Overview of Pre-term: Solution and results

    For personal use only Overview of Pre-term Solution and results ƒ The product has completed its phase 3 clinical trials and results are now being assessed ƒ In 2014, the product received ‘generally regarded as safe’ (GRAS) certification by the FDA ƒ Results from Clover’s DINO clinical trials indicat

  14. Slide 14: FY2016 Outlook & Priorities

    For personal use only FY2016 Outlook & Priorities • Leverage the two child policy in China, grow sales in the region • Develop new product applications in collaboration with customers • Organic growth with emphasis on Oceania, Asia and Europe • Diversify product portfolio and attract new customers •

  15. Slide 15: Thank you!

    For personal use only 23/03/2016 Thank you!

  16. Slide 16: Disclaimer

    For personal use only Disclaimer The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe s

Clover — Select Equities Healthcare & Wellbeing Investor Conference (May 2016) on 6ix